Show simple item record

dc.contributor.authorRheault, Michelle N.
dc.contributor.authorSavige, Judith
dc.contributor.authorRandles, Michael
dc.contributor.authorWeinstock, André
dc.contributor.authorStepney, Melissa
dc.contributor.authorTurner, Neil
dc.contributor.authorParziale, Gina
dc.contributor.authorGross, Oliver
dc.contributor.authorFlinter, Frances A.
dc.contributor.authorMiner, Jeffrey H.
dc.contributor.authorLagas, Sharon
dc.contributor.authorGear, Susie
dc.contributor.authorLennon, Rachel
dc.date.accessioned2020-04-01T09:55:29Z
dc.date.available2020-04-01T09:55:29Z
dc.date.issued2019-05-01
dc.identifier.citationRheault, M. N., Savige, J., Randles, M. J., Weinstock, A., Stepney, M., Turner, A. N., ... & Lagas, S. (2019). The importance of clinician, patient and researcher collaborations in Alport syndrome. Pediatric Nephrology, 1-10.en_US
dc.identifier.doi10.1007/s00467-019-04241-7
dc.identifier.otherNA
dc.identifier.urihttp://hdl.handle.net/10034/623291
dc.descriptionThis is a post-peer-review, pre-copyedit version of an article published in Pediatric Nephrology. The final authenticated version is available online at: https://doi.org/10.1007/s00467-019-04241-7en_US
dc.description.abstractAlport syndrome (AS) is caused by mutations in the genes COL4A3, COL4A4 or COL4A5 and is characterised by progressive glomerular disease, sensorineural hearing loss and ocular defects. Occurring in less than 1:5000, AS is rare genetic disorder but still accounts for >1% of the prevalent population receiving renal replacement therapy. There is also increasing awareness about the risk of chronic kidney disease in individuals with heterozygous mutations in AS genes. The mainstay of current therapy is the use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers, yet potential new therapies are now entering clinical trials. The 2017 International Workshop on Alport Syndrome in Glasgow was a preconference workshop ahead of the 50th anniversary meeting of the European Society for Pediatric Nephrology. It focussed on updates in clinical practice, genetics, basic science and also incorporated patient perspectives. More than 80 international experts including clinicians, geneticists, researchers from academia and industry, and patient representatives took part in panel discussions and breakout groups. This report summarises the workshop proceedings and the relevant contemporary literature. It highlights the unique clinician, patient and researcher collaborations achieved by regular engagement between the groups.en_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.urlhttps://link.springer.com/article/10.1007/s00467-019-04241-7#article-infoen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.titleThe importance of clinician, patient and researcher collaborations in Alport syndromeen_US
dc.typeArticleen_US
dc.identifier.eissn1432-198Xen_US
dc.contributor.departmentUniversity of Minnesota Masonic Children’s Hospital; Royal Melbourne Hospital; University of Manchester; Alport Syndrome Foundation; University of Oxford; University of Edinburgh; University Medicine Goettingen; Guy’s and St. Thomas' Hospital; Washington University School of Medicine; Alport UK; Manchester University Hospitals NHS Foundation Trusten_US
dc.identifier.journalPediatric Nephrologyen_US
dc.date.accepted2019-02-25
or.grant.openaccessYesen_US
rioxxterms.funderThe author time was supported by a Wellcome Senior Fellowship award (202860/Z/16/Z) to R.L. and a Research Project Award to R.L. from Kidney Research UK (K1199). The authors also acknowledge core funding from the Wellcome Trust (203128/Z/16/Z) to the Wellcome Centre for Cell-Matrix Research at the University of Manchester. Conflict of interest MR receives research funding from Regulus Therapeutics and Reata Pharmaceuticals. The other authors declare no conflicts of interests.en_US
rioxxterms.identifier.project202860/Z/16/Zen_US
rioxxterms.identifier.projectK1199en_US
rioxxterms.identifier.project203128/Z/16/Zen_US
rioxxterms.versionAMen_US
rioxxterms.versionofrecordhttps://doi.org/10.1007/s00467-019-04241-7en_US
rioxxterms.licenseref.startdate2020-05-01
rioxxterms.publicationdate2019-05-01
dc.dateAccepted2019-03-15
dc.date.deposited2020-04-01en_US
dc.indentifier.issn0931-041Xen_US


Files in this item

Thumbnail
Name:
ASWorkshop.pdf
Size:
1.490Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International